Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 5 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 9 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | MacroGenicsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | terminated | Phase 2 | 13 | Karyopharm Therapeutics IncINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03714555 | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine | terminated | Phase 2 | 1 | HonorHealth Research InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | terminated | Phase 2 | 9 | Baptist Health South FloridaOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03140670 | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | terminated | Phase 2 | 46 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | terminated | Phase 2 | 9 | Ismail GögenurOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer(RELEASE) | terminated | Phase 2 | 41 | PCI Biotech ASINDUSTRY | 14 | Sep 11, 2023 | clinicaltrials |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00601198 | A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer | terminated | Phase 2 | 4 | University of CincinnatiOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer(GEN206) | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04212026 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | terminated | Phase 2 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma(DEDUCTIVE) | terminated | Phase 1 / Phase 2 | 27 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects | terminated | Phase 2 | 73 | Antengene Therapeutics LimitedINDUSTRY | 3 | Jul 10, 2023 | clinicaltrials |
| NCT00551759 | Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | terminated | Phase 2 | 22 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT02489214 | Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer | terminated | Phase 1 / Phase 2 | 13 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03790111 | A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer(TELE-ABC) | terminated | Phase 2 | 53 | TerSera Therapeutics LLCINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial | terminated | Phase 1 / Phase 2 | 10 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03791398 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC(379) | terminated | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04784520 | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer | terminated | Phase 2 | 31 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 6, 2023 | clinicaltrials |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 11 | Peking UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2023source: clinicaltrials